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 What’s already known about this topic? NB-UVB is considered expensive. 
However, existing estimates of treatment costs are largely based on 
assumptions and do not consider treatment-associated savings. 
 What does this study add? We present comprehensive direct and indirect 
actual cost incurred for NB-UVB by a provider serving a population of 
420,000 over six years and identify significant savings achieved due to the 
reduced need of topical treatment. Our data necessitate a review of cost 
figures used in health technology appraisals. 
 
Abstract 
 
BACKGROUND: Narrowband – UVB (NB-UVB) treatment for psoriasis is 
considered expensive. However, existing data are based on estimates and do 
not consider indirect cost savings.  OBJECTIVES: To define actual costs of NB-
UVB incurred by the service provider, as well as treatment-associated cost 
savings. METHODS: Data linkage of (i) comprehensive treatment records, (ii) 
prescribing data for all NB-UVB treatment episodes spanning six years in a 
population of 420,000. Minimisation of data fluctation by: (a) compiling data from 
4 independent treatment sites, (b) use of drug prescribing unrelated to psoriasis 
as negative control.  RESULTS: NHS Tayside spent an average of £257 per NB-
UVB treatment course (£257 ± 63; range 150 – 286 across four independent 
treatment sites), contrasting sharply with the estimate of £1882 used by NICE 
UK. The cost of topical treatments averaged £128 per patient in the 12-months 
prior to NB-UVB, accounting for 42 % of overall drug costs incurred by these 
patients. This was reduced by 40% to £53 per patient over the 12 month period 
following NB-UVB treatment while psoriasis unrelated drug-prescribing remained 
unchanged, suggesting disase-specific effects of NB-UVB. Data were not due to 
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site-specific factors as confirmed by highly similar results observed between 
treatment sites operated by distinct staff. Finally, we detail all staff hours directly 
and indirectly involved in treatment, allowing direct translation of cost into other 
health care systems. CONCLUSIONS: NB-UVB is a low-cost treatment; cost 
figures currently used in health technology appraisals are an overestimate based 
on the data presented here. Creating or extending access to NB-UVB is likely to 
offer additional savings by delaying or avoiding costly third line treatments for 
many patients. 
 
Introduction 
 
Narrowband-UVB (NB-UVB) treatment has been shown to be effective in 
psoriasis in numerous clinical trials 1-5 and represents a cornerstone of treatment. 
However, the treatment has a reputation of being costly and difficult to 
implement. This perception is reflected in treatment guidelines, such as the most 
recently published British Association of Dermatology (BAD) guidelines which fail 
to even include NB-UVB in the biologic drug treatment pathway 
(recommendation R4 6). 
Defining the actual full cost of a non-drug based treatment is notoriously 
difficult. Thus, available data on the economics of UVB rely on assumptions on 
factors such as staff-related or estate cost 7 8 rather than actual financial 
turnover. This is chiefly do to the difficulties in obtaining high quality data. Rather 
than actually incurred cost, studies tend to focus on derived constructs such as 
Quality-adjusted Life Years (QALY), and not on precise delineation of actual 
expenditure (e.g. 9 summarily derives phototherapy cost from the National 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Health Tariffs). In addition, to the best of our knowledge, no published reports 
have considered the financial impact of NB-UVB associated cost savings by 
potentially reduced need for concomitant topical treatment following NB-UVB 
therapy. This lack of data is most likely due to the difficulties in retrieving 
comprehensive treatment records. 
As detailed previously, we have electronic access to complete records of 
all medical prescriptions filled for a population of 420,000 across Tayside/ 
Perthshire/ North-East Fife in Scotland 10. The population as such is marked by 
low demographic mobility as well as complete service provision through a single 
health care provider (NHS Tayside). In addition, phototherapy for the entire 
population is provided by one single department, dispensed at four separate 
treatment sites, and clinical treatment outcomes are prospectively recorded. We 
have most recently interrogated this comprehensive dataset to define the 
efficacy of NB-UVB treatment for psoriasis under real-world conditions 11. These 
data showed that NB-UVB treatment is highly effective and leads to a significant 
reduction in topical cream treatments prescribed for psoriasis 11.  
We here apply our uniquely comprehensive set of data to compile the expense 
incurred by a health care provider for the treatment of psoriasis with NB-UVB 
based on actual costs, taking into account savings achieved through reduced 
need for topical psoriasis treatment. Our data represent the actual cost incurred 
by the provider for all treatment episodes over a period of seven years, including 
the magnitude of variability associated with distinct staff operating treatment at 
separate sites, as well as fluctuations occuring over several years. Strikingly, we 
find that NHS Tayside achieved significant cost savings in drug dispensing in 
psoriasis patients treated with NB-UVB. In order to make our data generally 
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applicable, we also detail staff-hours allocated to NB-UVB treatment provision, 
thereby making local net cost transferable to other health care constellations. 
Since treatment with NB-UVB phototherapy can reduce the requirement and 
frequency of costly third line treatments like biologics, our data, suggest that 
investment in access to NB-UV treatment represents a viable cost-savings 
measure for health care providers. 
 
Methods 
Ethics statement: All data generated in this study were obtained in 
accordance with the Declaration of Helsinki and in compliance with local 
governance approval regulations (Caldicot number CSAppJF2101; the use of 
local Tayside phototherapy data was approved by the National Managed Clinical 
Network for Phototherapy, Photonet).  
STROBE statement: This is an observational cohort study. In accordance 
with the STROBE checklist 12 (see Supplement for full statement).  
Patient cohort: All methods pertaining to ascertainment of patient cohort, 
cohort refinement, cohort validation, prescribing data collection and refinement, 
quantification of psoriasis treatments, extraction of psoriasis-specific drug 
prescribing, data linkage, definition of NB-UVB treatment episodes, and study 
design have been described in detail 11. Statistical analyses shown in figure 2, 
table 2, and tests were performed using StatPlus software. 
Calculation of prescriptions charges. The data were accessed from the 
prescribing reports provided by IDS Scotland (http://www.isdscotland.org/Health-
Topics/Prescribing-and-Medicines/Publications/2016-06-28/2016-06-28-
Prescribing-Remuneration-Report.pdf). For details, see Supplement.)  
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Calculation of NB-UVB – incurred cost. Details of all staff cost are shown 
in supporting tables. Table S1 contains the number of treatment courses 
administered at each site throughout the observational period. Table S2 details 
the precise staff cost for all job roles involved in treatment.  Table S3 lists 
Estates cost. Table S4 calculates the overall treatment cost based on all data. 
Table S5 lists the summary of staff hours incurred, allowing calculation of costs 
for other economic regions based on local staff cost. Table S6 details the data 
used to derive the summary data in Table S5.  
 
Results 
 
The cost of topical psoriasis treatment. We collected data from all 
consecutive patients registered on the PhotoSys database, limiting analysis to 
the initial first-ever NB-UVB treatment administered for psoriasis, as described in 
detail previously 11. The patient cohort represents a significant fraction of all 
patients referred for specialist-supervised psoriasis treatment from primary care 
(n = 1749). As such, this cohort represents a longitudinal sample of patients 
suffering from moderate-to-severe psoriasis. The fact that they had been 
referred to secondary care implies that the managing GP assessed control of 
their disease as inadequate. In Tayside, primary care of psoriasis is limited to 
the use of topical treatment. Thus, a majority of patients in the cohort is likely to 
have received the maximal extent of topical treatment available at the time of 
referral. Table 1 lists the actual cost incurred by the healthcare provider. The 
combined prescription of all topical treatments between January 2008 and 
January 2015 amounted to £128 per patient or £35,713 per year. Of note, 
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despite similar numbers of prescriptions made for steroid-containing creams and 
‘psoriasis-specific’ creams, the latter account for a much higher cost per 
treatment (£19 vs. £92 per patient, respectively). In psoriasis patients, treatment 
of their psoriasis amounts to 42 % of all cost spent on prescription drugs (sum of 
steroid-, psoriasis-specific- and emollient topicals), as shown in Figure 1. 
We also analyzed spread and variation of treatment cost incurred per 
patient. As shown in Figure 2A (top), cost-per-patient was low overall, while 
increasingly small subgroups of patients generated increasingly high cost. This 
was also from box plot representation of the data (bottom) which shows that the 
median cost (yellow) was much lower than the average cost (red), with very few 
patients representing extreme outliers (green). This is summarised in table 2. 
We interrogated the data for evidence of other factors potentially 
influencing psoriasis-associated drug expenditure, but did not observe any 
significant differences between patients receiving treatment at different locations, 
nor was there an effect on cost by patient gender, or age at first NB-UVB 
treatment (age at diagnosis was not available). 
The impact of NB-UVB on cost of prescription drugs. We next analysed 
the cost incurred by NHS Tayside before and after an initial NB-UVB treatment 
course, respectively, in the 12-months interval prior to, as well as the 12-months 
interval after treatment (this was set to begin 4 months after initiation of NB-UVB 
treatment, as described in detail 11), respectively. As shown in figure 3, there 
was a statistically significant decrease in the cost of steroid creams and 
psoriasis-specific topical treatments, both overall annually and per-patient 
spending. There was no statistically significant change in prescription costs for 
any of three independent prescriptions classes (hypertension, depression, all 
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other prescriptions items combined, respectively, Figure 3).  Moreover, we have 
previously shown that the reduction in psoriasis-related prescriptions is not 
randomly spread among all patients but more pronounced in those patients 
exhibiting a better treatment outcome of NB-UVB detail 11, see tables 3 and S1 
therein). Therefore, several lines of evidence suggest that the observed changes 
in drug prescribing- and hence the cost- were unlikely to be merely associated 
by chance with NB-UVB treatment but much more likely directly caused by the 
treatment. 
Table 3 details savings made following NB-UVB treatment for each of the 
topical treatment drug classes. The overall savings amounted to £ 50.74 per 
patient, corresponding to approximately 40% reduction in per-patient prescription 
drug costs. On an individual level, the actual change in expenditure varied widely 
between patients. As shown in Figure 4, while most patients achieved cost 
savings both for steroid and psoriasis-specific topicals, there was a significant 
minority exhibiting an increase in drug expenditure. As expected, and detailed 
previously 11, the number of prescriptions was most markedly reduced in patients 
who had been recorded as ‘clear’ or ‘minimal residual disease’ following NB-
UVB treatment, further confirming that net reduction of cost was due to the effect 
of NB-UVB treatment.  
In addition to the drug cost, the NHS incurs a cost for each filled 
prescription as such. According to IDS-Scotland, these charges are 
approximately £0.70 per prescription (see Methods). We therefore quantified the 
number of prescriptions made for each of the topical treatment drug classes. As 
shown in table 4, there was a significant reduction in prescriptions, amounting to 
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overall savings of £ 2.48 per patient. Therefore, each NB-UVB-treatment course 
in Tayside is associated with a net savings of £53.22 in topical treatments cost. 
Staff-related and staff-unrelated cost of NB-UVB treatment. The cost 
incurred by NB-UVB treatment involves a number of items including both staff 
and non-staff related costs. We identified each of these cost components for 
each of the individual treatment sites analysed (Table 5). Since the actual cost 
per treatment critically depends on the actual numbers dispensed we also 
analysed the fluctuation of annual treatment number over the the entire 
observational window (Table S1) and calculated the average cost per treatment 
by using the average, thereby safeguarding the data against short-term 
fluctuations. We observed a very low overall variability in treatment number over 
the entire observational window (Table 5, top row). The staff cost listed in table 5 
are not estimates but rather represent the actual staff hours allocated to the 
various aspects of NB-UVB administration at each of the four sites, as shown in 
detail in Table S2. The average costs across all sites, both absolute and by 
relative contribution, are shown in Figure 5. As expected, the costliest 
component is staff time, accounting for 92 % of cost. “Nurse time” constitutes the 
largest share, (84 % of total cost, for details, see Table S4, boxed “relative 
contribution”) where this item includes treatment administration, documentation, 
data entry, letter dictation, as well as continuous professional training. 
Furthermore, the staff cost shown in Table 5 includes employer pension, as well 
as National Insurance contributions, respectively (for details, see Table S2). 
The variability of treatment cost across treatment sites. Cost of any highly 
staff-dependent medical treatment could be significantly modified by site-specific 
factors non-existent in other centres and hence render the resulting data less 
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informative. Since we had access to site-specific data, we therefore also 
analysed the variability in cost between separate centres run by distinct staff 
(table 5). We did not observe an overall trend between large (NW), medium 
(Perth), and small (St. Andrews, Stracathro) centres, respectively. Rather, 
variation in cost appear to be primarily related to the number of treatments 
administered per staff hours. Taking into account the various number of 
treatments occurring across the four sites between 2008-2015, NHS Tayside 
spent and average of £253 ± 64 for each NB-UVB course including all overhead 
costs (Table S4). Given that each treatment lasted an average of 29.7 ± 10.5 
sessions 11, one session generates a cost of £8.50. 
The allocation of staff hours to NB – UVB treatment. Since the cost for 
phototherapy is highly salary – dependent, we also listed the actual staff hours 
required to dispense treatment in an effort to render our data transferable to 
other economic contexts, as long as local salary scales are known (summarised 
in Table S5 and detailed in Table S6). One important aspect of this is that 
treatment is not carried out by single members of staff but spread into job plan 
components of various staff. For example, even at the smallest treatment site 
(Stracathro), primary treatment is shared between five local staff, each 
contributing roughly 20% of their job plan. This set-up may be contribute to 
overall resilience of service, leading to overall low fluctuation in treatment 
numbers, as detailed above. One complete NB-UVB course required a total of 
0.45 ± 0.14 staff hours, including direct and indirect support roles. By substituting 
local salary scales, these data allow calculation of analogous cost likely to be 
incurred by service providers operating in distinct economical contexts. 
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Discussion 
 
The cost of phototherapy: On average, NHS Tayside spent £257 for each 
NB-UVB treatment course administered for psoriasis (including all staff 
overheads) and saved £53. The resulting net average cost of £204 makes this 
obviously a very economical treatment option. In more general terms, one 
complete NB-UVB course required an average of 0.45 ± 0.14 staff hours. These 
figures represent averages across four separate treatment sites and spanning 
six years, thereby eliminating any spurious fluctuations over time or bias inherent 
in local factors specific to individual treatment sites. As such, the real cost of NB-
UVB contrasts sharply with the previous NICE-UK assignment of £1882 per NB-
UVB treatment course 13. Notably, the actual net expenditure reported here is 
less than even that of methotrexate cited by NICE based on the BNF drug tariff 
(£404 per annum 13). 
Our data contrast with previously reported studies. One real-world study 
from Finland assigned a cost of €755 for a course of NB-UVB with an average of 
14 sessions per course 14. However, it is not clear how the price-charge of €32 
per session cited therein related to the cumulative price. In addition, these 
authors included external items, e.g. lab cost, and arbitrarily levied NB-UVB 
charges which are not inherent treatment cost but rather form part of an overall 
profitable pricing structure. Another Finnish-based real-world study from 2009 
assigned €39/ annum to methotrexate and €351/annum to acitretin but does not 
quantify NB-UVB cost, despite stating that this was applied to 36% of patients 15. 
One recent U.S.-based review assigned a direct treatment cost of office-based 
NB-UVB as ranging between $1414 - $6676 per course based on three cited 
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studies. However, these figures were compiled based on estimates, rather than 
actual cost and without attempting to explain the huge variability in the cited 
studies 16. Again, the notably higher cost, aside from locally varying cost of labor, 
likely reflects cost accruing within a for-profit business model. Even in England, 
which still has a national health service, services such as phototherapy are not 
evaluated on the basis of real cost but assigned tariffs. For phototherapy, the 
assumed tariff is £74 per session for patients older than 13 and £86 for 12 years 
and younger 17 (sheet 1a APC & OPROC 17.18., codes JC47A and JC47B), with 
is in striking contrast with the actual cost (£8.50 per session, see above). Clearly, 
this would constitute a disincentive to provide treatment. Numerous other health 
economic studies focusing primarily on more expensive biologics have assigned 
a cost to NB-UVB as a comparator treatment. However, these studies generally 
focus on “cost per PASI75”, using data from controlled trials rather than real-
world direct cost, as detailed here. Thus, the data reported here, to the best of 
our knowledge, represent the most comprehensive direct measurement of actual 
cost accrued for NB-UVB treatment to date. 
Importantly, It should be noted that the cost of NB-UVB we describe here 
does not come at the price of reduced efficacy. Rather, we recently documented 
that NB-UVB is highly effective in psoriasis under real-world conditions 11. Taking 
together available evidence, NB-UVB is not only effective but by far the most 
economical treatment option for psoriasis inadequately controlled with topical 
treatments, perhaps with the exception of methotrexate. In contrast to NB-UVB, 
however, methotrexate is associated with a number of adverse events, as we 
have recently quantified both in clinical trials and under real world conditions 10, 
18. In conjunction with our analysis of the efficacy of NB-UVB 11, our data 
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therefore dispel a widely held implicit notion that NB-UVB is expensive (as 
reflected in the NICE statement cited above) and ineffective. As such, from the 
perspective of health care provision, extending access to and widening the 
implementation of NB-UVB deserves serious consideration. 
Limitations: The present study has a number of obvious limitations. Firstly, 
we only included initial NB-UVB-courses and only those administered for 
psoriasis, as dictated by the study design 11. Secondly, we did not consider other 
phototherapy applications, especially PUVA, which are commonly offered by the 
same centres. Third, we did not consider non-provider cost by patients (or 
employers), including travel and absence from work (for indicative data on the 
latter, see 9). Such costs can be reduced by provision of a comprehensive 
phototherapy service including home phototherapy19, 20 and patient self-
administration phototherapy21 for those who cannot readily attend the hospital 
units (which must have adequate opening hours). Fourthly, we did not perform 
health economic modelling, such as, e.g., modelling of treatment outcomes to 
derive QALY-related cost. Finally, our analysis provides direct cost only for the 
UK NHS-based hospital context. However, we have provided detailed functional 
staff-hour allocation which we hope will enable readers to translate cost into 
other salary-contexts (see below). 
Cost of topical treatment in psoriasis: In the course of this study we also 
define the actual cost associated with topical treatment for psoriasis on a 
population level. Thus, in Tayside, Scotland, treatment with creams for psoriasis 
accounts for 42 % of the total cost incurred by patients with disease of sufficient 
severity to warrant referral to secondary care (Figure 1). The actual annual cost 
of these creams (£128, Table 2) is much lower than the NICE – UK estimate 13, 
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possibly reflecting the previously noted relative under – treatment of psoriasis 
under real world conditions. By way of comparison, the data in Table 1 show that 
the cost incurred per patient for psoriasis drugs is commensurate to the per-
patient treatment cost for hypertension in patients requiring three different 
hypertensive agents and a nurse specialist review 22. It is remarkable, therefore, 
that this cost is reduced by an average of approximately 40 % over the 12-
months interval following NB-UVB treatment. To the best of our knowledge, this 
is the only psoriasis treatment confirmed to incur directly proven significant net 
savings in topical treatment cost to date. Of note, our data show a non-Gaussian 
distribution of cost (Figure 2) which should inform future model development. 
Moreover, the cost of topical treatment for psoriasis, as detailed here, represents 
a comprehensive real-world population sample, as opposed to a treatment 
cohort subject to selection and reporting bias, as discussed previously 11. 
Therefore, these data (Table 2) should prove valuable to regulating bodies, such 
as NICE, when estimating cost effectiveness for alternative treatments. 
Indirect savings of NB-UVB: The actual cost of NB-UVB in every day 
practice is likely to be even lower than reported here for three reasons. Firstly, 
the average efficacy, and thus indirect savings in topical creams are likely even 
more pronounced in subsequent NB-UVB courses, since patients experiencing 
no or limited benefit in the initial treatment episode are less likely to undergo 
repeat treatment, thereby introducing a bias toward greater relative efficacy. 
Secondly, the number of outpatient visits and GP reviews are likely also reduced. 
Thirdly, administration of 3rd line systemic or biologic treatments will be delayed, 
or even avoided, in some patients, adding further savings. 
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Added benefits of providing NB-UVB: Although considered here for 
psoriasis, NB-UVB is also efficacious in other conditions. For example, oral 
systemic treatments for pruritic dermatoses often prove ineffective in 
establishing symptomatic control. Our data illustrate that anti-histamine 
consumption is reduced following administration of NB-UVB, even in psoriasis 
patients 11, in confirmation of the widespread observation that NB-UVB is 
effective to control pruritus 23, 24. Other common conditions, notably eczema 25, 26 
and urticaria 27, also show good response to this treatment, thereby adding to 
indirect net savings by creating synergy on staff and equipment cost. 
The cost of newly establishing access to NB-UVB: How much would it 
cost to newly establish access to NB-UVB locally? The data provided in Tables 
S5 and S6 allow calculation of cost faced by providers when setting up or 
extending NB-UVB treatment facilities. For example, the small treatment centre 
in Stracathro allocates 33h per week, distributed to 20% of a 40h work-week 
among four nurses, respectively, to run the service, thus allowing sufficient 
cross-cover for staff absence. Consultant and other medical supervision is 
allocated at 1h / week; equipment/ maintenance/ estate cost need to be added 
but are of lesser cost implication. Using the NHS salary costs (Table S2) the 
entire staff-cost package, including pension/insurance contribution, for this site 
amounts to £ 30,750 per year, in return for a total of 152 NB-UVB and 81 PUVA 
treatment courses. The staff cost can be readily adapted to local salary scales 
using the staff hour breakdown given in table S6. Even in health care systems 
where the additional savings gained through reduced drug treatments (£53 per 
treatment) are not allocated to the NB-UVB service provider, and allowing for 
added cost for implementation, both set-up and running costs are recouped by 
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delaying the need to prescribe biologic treatment by one year in as few as three 
patients (Scottish Medicines Consortium cost template, 28). It is also worth 
pointing out that Tayside, Scotland, is a very rural clinical setting, requiring 
patients to travel comparatively large distances in order to attend for treatment 
with relatively large impact on loss of work hours. It is likely that patient 
acceptance and compliance will be even easier to achieve in urban areas. Given 
the added benefits of this service, our data suggest that implementation of NB-
UVB service not only offers effective treatment, but may be highly attractive in 
economic terms for providers. 
Position of NB-UVB in psoriasis treatment pathways. The efficacy and 
cost- effectiveness of NB-UVB treatment is difficult to reconcile with its position 
in various current psoriasis treatment guidelines. Thus, the current British 
Association of Dermatologist (BAD) guidelines do not even consider NB-UVB on 
the pathway to Biologics treatment 6. Similary, many guidelines consider NB-
UVB as a treatment option but not one which should be actively encouraged. In 
these cases, safety is cited as a reason to discourage treatment. Thus, the 
updated Canadian guidelines state: “it has not been established whether NB-
UVB is carcinogenic in humans; however, speculation based on nonclinical data 
suggests that NB-UVB could be more carcinogenic than natural [..] sunlight. [..] 
in the absence of [safety] evidence, it is prudent [..] to reduce exposure to NB-
UVB radiation.”29 Similarly, the Spanish guidelines erroneously equate NB-UVB 
with PUVA, by stipulating that Biologics may be used in patients “at risk of 
toxicity with [..] phototherapy” 30, while obviously drug toxicity is known only for 
PUVA but entirely absent in NB-UVB. The current guidelines of the  U.S. 
American Academy of Dermatology also do not even suggest that NB – UVB 
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ought to be actively considered before moving to systemic treatments. Likewise, 
the U.S. National Psoriasis Foundation actively opposes any effort to apply cost-
effective treatments ahead of more expensive alternatives (called “step therapy”), 
lobbying actively for legislation to ban this approach. Clearly, NB-UVB poses 
significant obstacles, not measured here, including non-provider costs including 
travel and absence from work, time commitment and scheduling difficulties. 
These issues will limit practical use in many cases. These limitations not 
withstanding, treatment recommendations on psoriasis in many countries do not 
reflect the efficacy of NB – UVB analysis 11, nor its cost effectiveness. The data 
presented here provide a rationale to review such guidelines. 
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Tables 
 
 
Table 1. Cost incurred by NHS Tayside for psoriasis-associated treatment in 
primary care1 
 
Drug class Nr of 
patients on 
treatment 
Cost (£) 
  Per patient Per year (all patients) 
Pso-specifics creams3 1461 92 21512 
Steroid-creams 1287 19 3913 
Emollients 1262 17 3434 
Systemic treatments4 55 3.6 32 
All psoriasis – related scripts   132 28890 
Anti-depressives 301 7.7 371 
Anti-hypertensives 334 7.3 390 
Anti-histamines 46 1.4 10 
All other prescriptions 1626 161 41897 
All psoriasis – unrelated scripts  177 42668 
1Data represent all prescriptions made out for psoriasis patients referred for 
secondary care treatment and subsequently receiving NB-UVB treatment 
between January 2008 and January 2015 (N = 1749, see Methods).  
2 Sum of steroid-containing-, psoriasis-specific- and emollient topical 
prescriptions. 
3Defined by British National Formulary code 13.5.2 for topical agents indicated 
solely for psoriasis (e.g. calcipotriol, dithranol, coal tar), as detailed in 11. 
4Prescriptions for methotrexate (n = 271), acitretin (n = 10), and cyclosporine (n 
= 5).  
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Table 2. Distribution of cost for topical psoriasis treatment in NHS Tayside.1 
 
 
Annual Cost/ patient  Steroid Creams Pso-specific Topicals Emollients 
 Cost (£) 
Average ± s.d. 26 ± 29 109 ± 111 23 ± 27 
Median 16 73 13 
75% percentile 32 139 27 
Top outlier 249 920 226 
 
1Data shown detail cost for those patients receiving steroid cream (n = 1287), 
topical psoriasis cream treatments (n = 1461), or emollient cream treatment (n = 
1262), respectively.  
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Table 3. Cost reduction for topical psoriasis treatments afterNB-UVB treatment1 
 
 Steroid 
creams 
Psoriasis-
Specifics 
Emollients All 
topicals 
Average per 
patient 
£ 7.43 £ 39.26 £ 4.05 £ 50.74 
Median per 
patient 
£ 3.81 £ 29.46 £ 1.61 £ 34.88 
Annual2 £ 2079 £ 10987 £ 1133 £ 14199 
1Annual reduction in cost for drug prescriptions for psoriasis after one single 
course of NB-UVB phototherapy. For details see text. 
2Annual savings are calculated for 12 months out of the total 75 months 
observational window. Within the entire cohort (n = 1749), this number is 
equivalent to savings made for n = 280 patients. 
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Table 4. Change in the number of prescriptions made out for psoriasis before 
versus after NB-UVB treatment.1 
Cost of prescriptions 
(£) 
per year per patient 
 Before 
UV 
After 
UV 
Savin
gs 
Before 
UV 
After 
UV 
Savin
gs 
Steroids 854 495 250 3.05 1.77 0.90 
Pso-Topicals 998 562 304 3.56 2.01 1.09 
Emollients 762 566 137 2.72 2.02 0.49 
All scripts 2613 1623 692 9.34 5.80 2.48 
1Numbers shown are the absolute incurred prescription fees incurred by NHS 
Tayside as remuneration for pharmacies for filling prescription made out for all 
psoriasis patients (n = 1749) in the 12-month interval before, or after NB-UVB 
treatment, respectively, calculated for treatments occurring within a single year, 
or per patient, as shown in the table (for details see Methods). 
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Table 5. The cost of NB-UVB treatment in NHS Tayside.1 
 Dundee Perth Stracathro St. Andrews 
Centre size Large Medium Small Small 
Courses administered2 430 ± 22 233 ± 24 112 ± 11 130 ± 15 
Staff – related costs3 
Photobiology technician 19 1 1 1 
Nurse4 203 260 123 232 
Administrative support5 5 2 1.4 1.8 
Consultant supervision6 31 3 6 7 
Non-consultant clinician7 8 7 3  
Non staff – related costs 
Equipment7 7 7 12 14 
Medical Physics8 1 2   
Estate9 0.04 0.05 0.08 0.1 
Total 274 282 145 256 
1Data show the cost incurred per treatment course rounded to the nearest £ (see 
table S4) 
2 Average ± s.d. between 2010 – 2015. One course consists of 30 ± 10 (average 
± s.d.) treatment sessions, with minimal variation between the four different 
centers, as previously shown (11, Figure 5d therein).   
3For salary components, including indirect cost (pension and National insurance 
cost), see Table S2. 
4Cost includes staff hours allocated to treatment administration, documentation, 
data entry, letter dictation, continuous professional training. Data shown are 
derived from salary scales detailed in Table S2 for each of the centres.  
5Secreterial support, numbers shown cover staff hours allocated to typing and 
appointment booking. 
6Includes staff hours by both consultant and registrars allocated to phototherapy 
as per job plan (see Table S6). 
7Based on purchasing price of £1603 as directly incurred by NHS Tayside in 
2015 for one NB-UVB cabinet including depreciation, average lifetime, 
replacement kit (bulbs). Cost of two units used for the Dundee site (Ninewells 
hospital).  
8Includes maintenance, lamp calibration, as provided by Medical Physics. 
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9Based on published cost for cleaning, property maintenance, energy, and rates 
per m2. in NHS Tayside (for details see table S3). 
 
Supporting Information 
 
File: “Supplement”. 
This file contains the extended STROBE information as well as details on 
procuring data on drug prescription costs. 
 
File: “Table S1 – S6”. 
This file contains detailed information on the number and cost of NB – UVB 
treatment courses administered across all treatment sites in Tayside / Scotland 
during the observational window. 
 
Legends to Figures 
Figure 1. Relative contribution of prescribed drugs to overall treatment cost 
incurred by NHS Tayside for psoriasis patients between January 2008 and 
January 2015. Numbers shown represent the percent of total (100 % = £ 86,493 
per year, see Table 1). H1- antihistamines, Depr- anti-depressive drugs, HTN- 
antihypertensives. The definition ‘Pso-creams’ refers to topical treatments only 
prescribable for psoriasis in the British National Formulary (BNF code 13.5.2) 
and comprises calcipotriol, calcipotriol with betamethasone, calcitriol, coal tar 
products, dithranol, salicylic acid compounds, tacalcitol, as well as tazarotene.  
 
 
Figure 2. The distribution of cost for topical psoriasis treatments in primary care 
in Scotland. Top: Histogram plots for all patients (n = 1749) incurring annual 
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costs up to the threshold amounts given in £ on the x-axis for each of the drug 
classes indicated. Bottom: Box plots showing percentiles, median, average costs, 
as well as distribution of outliers, as indicated in the color coded lines. 
 
Figure 3. The effect of an initial course ofNB-UVB treatment on the cost of 
prescription for topical psoriasis medicines. The figure shows the total cost 
incurred by NHS Tayside, expressed in £ before (dark shaded), and after (light 
shaded)NB-UVB treatment, respectively. Top: cost per annum for all patients, 
Bottom: annual cost per patient. * p < 0.01 in a paired t-test. Depr- 
antidepressive drugs, HTN- antihypertensive drugs 
 
Figure 4. The distribution of change in cost for drugs prescribed for psoriasis 
after versus before one course of NB-UVB phototherapy. Histograms show the 
actual change in cost (given in £) across all patients for the drug class indicated 
at the top of each plot. 
 
Figure 5. The cost of administering NB-UVB phototherapy in Tayside, Scotland. 
(A) Actual cost shown as average ± s.d. of costs incurred across individual sites, 
as detailed in Table 5. Cost are shown on a log-scale so as to visualise both 
high- and low-cost components, respectively. (B) Pie chart illustrating the 
percentage contribution of each cost component shown in (A) where actual 
percent cost are shown for each item. 
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